4 completed, 1 recruiting, 1 unknown, 1 withdrawn. 7 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 4, Recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 3 | Recruiting 1, Unknown 1, Withdrawn 1 |
Follow Unresectable Malignant Neoplasm: new trials by email Literature Review of Unresectable Malignant Neoplasm trials Research Report on Unresectable Malignant Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer Radiotherapy, Nimotuzumab, S-1 - Esophageal Cancer, Chemoradiotherapy | Phase 2 | Completed | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 55 | 2019-11-14 | 2024-05-16 |
| Chemoradiotherapy in Unresectable Esophageal Cancer Radiotherapy, Albumin-Bound Paclitaxel, Cisplatin - Esophageal Cancer, Chemoradiotherapy | Phase 1 / Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 105 | 2019-10-01 | 2024-12-13 |
| ImmunoPET With an Anti-CD8 Imaging Agent Anti-CD8 PET imaging agent - Metastatic Cancer, Unresectable Malignant Neoplasm | Phase 1 / Phase 2 | Unknown | University Medical Center Groningen | 47 | 2019-02-14 | 2024-05-03 |
| Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer Durvalumab, IMRT 50 Gy + FOLFOX4 simplifIed (oxaliplatin, leucovorin, 5-FU) - Esophagus Cancer, Unresectable Malignant Neoplasm | Phase 2 | Completed | UNICANCER | 112 | 2018-12-05 | 2025-11-18 |
| QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma. Aldoxorubicin Hydrochloride, ALT-803, ETBX-051 - Chordoma, Unresectable Malignant Neoplasm | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2018-08-31 | 2025-02-21 | |
| Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors Atezolizumab, Cobimetinib - Skin Squamous Cell Carcinoma, Appendix Adenocarcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 49 | 2017-04-07 | 2025-05-28 |
| Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma Pembrolizumab - Unresectable Malignant Neoplasm, Melanoma | Phase 2 | Completed | St. Louis University | 10 | 2015-01-01 | 2019-06-20 |
Esophageal Neoplasms (3) · Neoplasm Metastasis (2) · Adenocarcinoma (1) · Adenocarcinoma, Mucinous (1) · Carcinoma, Squamous Cell (1) · Chordoma (1) · Melanoma (1) · Neoplasms (1)
Neoplasms (6) · Neoplasms by Histologic Type (4) · Neoplasms by Site (4) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Esophageal Diseases (3) · Gastrointestinal Diseases (3) · Gastrointestinal Neoplasms (3) · Head and Neck Neoplasms (3) · Carcinoma (2) · Neoplasms, Germ Cell and Embryonal (2) · Neoplasms, Glandular and Epithelial (2) · Neoplastic Processes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2)
Radiotherapy (2) · 130-nm albumin-bound paclitaxel (1) · ALT-803 (1) · Albumin-Bound Paclitaxel (1) · Cetuximab (1) · Cisplatin (1) · Cyclophosphamide (1) · Fluorouracil (1) · Leucovorin (1) · Oxaliplatin (1) · Platinum (1) · S 1 (combination) (1) · atezolizumab (1) · avelumab (1) · cobimetinib (1)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2) · ImmunityBio, Inc. (1) · M.D. Anderson Cancer Center (1) · St. Louis University (1) · UNICANCER (1) · University Medical Center Groningen (1)
United States (3) · China (2) · France (1) · Netherlands (1)
Anouchka Modesto, Doctor (1) · E. G.E. de Vries, MD, PhD (1) · John M Richart, MD (1) · Kanwal P Raghav (1) · Laurent Quero, Doctor (1) · Xin Wang, MD (1)
2018 (1)